Main research interest: Our primary research efforts are dedicated to identifying biomarkers for the diagnosis and prognosis of diseases, particularly those associated with inflammation. We focus on the cancer microenvironment, including exosome‑associated microRNAs, and explore their target genes as potential therapeutic targets. Our goal is to translate laboratory discoveries into clinical applications, bridging the gap between bench and bedside. Our multidisciplinary team, which includes urologists, pathologists, and basic scientists, works closely together to address clinically relevant questions through biological research. We utilize a workflow that integrates patient‑derived data with in vitro experiments, aiming to uncover biomarkers for clinical use and to elucidate their molecular mechanisms of action. Currently, our main focus is on prostate cancer (PCa) and its microenvironment, particularly periprostatic adipose tissue‑derived vesicles. We are dedicated to identifying new molecular biomarkers from these secreted vesicles that are useful for predicting the aggressiveness of prostate, bladder, and kidney cancer. We have ongoing projects on PCa progression and the search for prognostic factors in hormone‑sensitive prostate cancer (mHSPC) non‑responders to therapies

Link Website

GEIVEX groups 2025

GEIVEX groups 2025

You can dowload the interactive pdf with all the groups: here